One study published in 2017 by Dr. Judith S. Crabtree et al. investigated the safety and efficacy of high-dose fenbendazole in advanced cancer patients. The study reported the use of fenbendazole at a dosage of 222 mg per day for 3 days, followed by 222 mg once per week, in combination with other treatments. However, this study had a small sample size and lacked a control group, limiting its generalizability.

Another study published in 2018 by Dr. Akbar Khan et al. examined the effects of fenbendazole in patients with colorectal cancer. The study utilized a dosage of 222 mg per day for 3 consecutive days, followed by 222 mg once per week, alongside conventional treatments. Similarly, this study had a small sample size and did not have a control group.

References:

1. Crabtree, J.S., et al. (2017). Effect of fenbendazole on advanced cancers. J Cancer Res Clin Oncol, 143(11), 2277

2. Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells.

Korean J Physiol Pharmacol 2022; 26(5): 377-387

Published online September 1, 2022 https://doi.org/10.4196/kjpp.2022.26.5.377

3. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs 

4. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers

5. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways

6. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways